The number of new coronavirus mutations has increased, and the mutant strains are prevalent in many countries. The trend of the new crown pneumonia epidemic is currently difficult to predict. While the new crown vaccine has achieved effective prevention and control, the demand for effective drugs for the new crown virus has become more and more urgent.

So, which drug is developing the fastest? Is there a specific "timetable" for the new crown special medicine?

Relevant data show that in terms of antibody drugs, the fastest progress is currently the neutralizing antibody combination therapy jointly developed by Tsinghua University, Shenzhen Third People’s Hospital and Tengsheng Huachuang mentioned above.
According to reports, the phase III clinical trial of the drug led by the National Institutes of Health (NIH) is being carried out in 7 countries including the United States, Brazil, and the Philippines. The results of the study are optimistic, and the combined treatment of BRII-196 and BRII-198 can reduce 78%. of hospitalizations and mortality, and is most likely to be the first to receive emergency use authorization in developed countries such as the United States.
In my country, the R&D team has submitted the conditional listing application materials to the State Food and Drug Administration on a rolling basis on October 9, and is expected to be approved (with conditions) for listing by the end of December.

Source: Science and Technology Daily

Responsible editor: Wu Guanwen
Disclaimer: All the manuscripts indicating the source of China Jiangsu Net are the original works of this official account, welcome to forward, please indicate the source! Some manuscript pictures are from the Internet, and the copyright belongs to the original author.